Nephrology

Dialysis Facilities Persevered Through Hurricane Ida

Publish Date September 15, 2021

Impaired communications, power outages, and clean water availability caused by Hurricane Ida were among the challenges facing dialysis providers in Louisiana.

Study: Closed-Loop Insulin Therapy Safe, Effective in Diabetes Requiring Dialysis

Publish Date September 7, 2021

Compared with standard insulin therapy, closed-loop insulin therapy was associated with less time in hypoglycemia.

Home Hemodialysis Failure Linked With Higher Death Risks

Publish Date September 3, 2021

A greater understanding of outcomes after home HD treatment failure may help inform clinical decision making and advanced care planning.

Combination of eGFR and UACR Better Predicts CKD Progression

Publish Date September 1, 2021

Using changes in UACR and eGFR as an alternative outcome for kidney failure in trials of CKD progression warrants further evaluation, according to investigators.

FDA to Review sNDA for Purified Cortrophin Gel for Multiple Indications

Publish Date September 1, 2021

Purified Cortrophin Gel is a purified adrenocorticotropic hormone.

Nephrology Referrals ID Many Patients at Low Risk for Progression

Publish Date August 30, 2021

Potential referral volume could be reduced if referral was restricted to patients with predicted risk ≥1% in addition to laboratory criteria

Korsuva Approved for Chronic Kidney Disease-Associated Pruritus

Publish Date August 25, 2021

The approval was based on data from the pivotal phase 3 KALM-1 and KALM-2 trials, as well as data from an additional 32 clinical studies.

BMI Fluctuations May Predict Poor Outcomes in CKD

Publish Date August 24, 2021

High variability in body mass index is associated with an increased risk for death, requiring kidney replacement therapy, myocardial infarction, and stroke, investigators concluded.

The Potential Dangers of Ketogenic Diets in Kidney Disease

Publish Date August 19, 2021

A recent review underscores the possible adverse effects of ketogenic diets, including increased risks for heart disease, cancer, diabetes, and kidney stones.

Dapagliflozin Reduces Kidney and Cardiovascular Events Among Patients With Chronic Kidney Disease

Publish Date August 19, 2021

Investigators report findings from the Dapagliflozin and Prevention of Adverse outcomes in CKD (DAPA-CKD) study.